Skip navigation

Inivata Publishes Results of Analytical Validation for InVisionFirstTM-Lung ctDNA Liquid Biopsy

09 April 2018

Publication support robustness and reproducibility of the InVision™ platform.

Industry-leading sensitivity and specificity shown across all classes of genomic alterations relevant to non-small cell lung cancer.


Research Triangle Park, NC and Cambridge, UK, March 19 2018 -- Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces the publication of the analytical validation of its InVisionFirst-Lung targeted advanced sequencing test. The results were published in PLoS ONE[i] and build on previous development work on the InVision platform also recently published in PLoS ONE[ii]. 

The InVisionFirst-Lung test is intended to aid clinicians in treatment decisions for non-small cell lung cancer (NSCLC), using targeted advanced sequencing technology to detect cancer genomic alterations in selected genes from circulating tumor DNA (ctDNA) isolated from plasma samples. 

The test provides comprehensive genomic profiling from circulating tumor DNA, to identity actionable genomic alterations in genes commonly mutated in NSCLC and other cancer types.  The assay has been developed to detect point mutations, indels, amplifications and gene fusions that commonly occur in NSCLC. 

Given the low concentration of ctDNA relative to total cell-free DNA in circulation, detection of somatic mutations from ctDNA requires very high sensitivity to deliver clinical benefits to the broadest patient population. InVisionFirst-Lung was shown to demonstrate industry-leading sensitivity and specificity across all classes of genomic alterations relevant to NSCLC. 

Michael Stocum, Chief Executive Officer of Inivata, said: “This ongoing rigorous validation showed the InVisionFirst-Lung assay to be highly sensitive, specific and robust, achieving the analytical requirements for the delivery of valuable clinical information to aid the treatment of lung cancer. We believe we have demonstrated levels of sensitivity and specificity beyond those published for other liquid biopsy platforms and which could bring significant benefits for clinical applications.” 

Study Summary
  • Study with almost 1,000 samples demonstrated exceptional limit of detection and high reproducibility for all types of clinically relevant somatic mutations
  • 99.48% sensitivity for single nucleotide variants (SNVs) present at a variant allele fraction (VAF) range of 0.25%-0.33%
  • 92.46% sensitivity for indels at 0.25% VAF and a high rate of detection at lower frequencies while retaining high specificity (99.9997% per base)
  • For VAFs as low as 0.06-0.08%, more than half of SNVs were detected 
  • ALK and ROS1 gene fusions also detected, as well as DNA amplifications in ERBB2, FGFR1, MET and EGFR with high sensitivity and specificity
  • ALK and ROS1 fusions were detected down to 0.06% VAF demonstrating the ability to detect rare genomic alterations at very low but clinically meaningful allele frequencies
  • Comparison between the InVisionFirst-Lung test and a select group of single analyte assays using digital PCR (dPCR) showed high concordance with a positive agreement of 100% 

ENDS
                                                                                                                                                                                                    

Media Contacts:
Consilium Strategic Communications 
Chris Gardner/Laura Thornton 
inivata@consilium-comms.com
+44 (0)20 3709 5700

Karen Chandler-Smith
karen.chandler-smith@inivata.com
+44 (0)7900 430235